Pharmaceutical companies in the United States by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 19 pharmaceutical companies in the United States ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Bristol-Myers Squibb (12.9). Figures as of 20 Nov 2026, 12:18 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- PLN 15.17T
- Countries
- 1
- Not ranked
- 25no P/E ratio on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | PLN 18.3B | PLN 167.13 | 0.48% down | 82% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | PLN 80.4B | PLN 600.06 | 1.06% down | 66% down | ||
| 3 | Bristol-Myers SquibbBMY · Health Care | 12.9 | PLN 484.1B | PLN 236.83 | 2.05% down | 26% up | ||
| 4 | ZoetisZTS · Health Care | 13.7 | PLN 133.3B | PLN 327.96 | 5.59% down | 34% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | PLN 387.7B | PLN 3,748.22 | 2.35% down | 22% up | ||
| 6 | United TherapeuticsUTHR · Health Care | 21.1 | PLN 96.7B | PLN 2,269.62 | 3.16% down | 18% up | ||
| 7 | Protagonist TherapeuticsPTGX · Health Care | 26.2 | PLN 32.9B | PLN 503.45 | 2.47% down | 45% up | ||
| 8 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | PLN 535.9B | PLN 2,113.57 | 2.94% down | 22% up | ||
| 9 | Abbott LaboratoriesABT · Health Care | 38.8 | PLN 730.3B | PLN 421.65 | 0.58% down | 19% down | ||
| 10 | PfizerPFE · Health Care | 39.3 | PLN 637.2B | PLN 111.80 | 1.85% down | 10% up | ||
| 11 | Johnson & JohnsonJNJ · Health Care | 40.5 | PLN 2.61T | PLN 1,084.43 | 2.04% down | 31% up | ||
| 12 | Eli LillyLLY · Health Care | 43.9 | PLN 4.89T | PLN 5,484.75 | 2.29% down | 28% up | ||
| 13 | Royalty PharmaRPRX · Health Care | 44.3 | PLN 158.1B | PLN 274.90 | 1.38% down | 74% up | ||
| 14 | AbbVieABBV · Health Care | 48.7 | PLN 2.03T | PLN 1,151.01 | 0.86% down | 20% up | ||
| 15 | Corcept TherapeuticsCORT · Health Care | 48.9 | PLN 28.9B | PLN 263.78 | 4.15% down | 16% down | ||
| 16 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | PLN 30.3B | PLN 86.83 | 2.24% down | 79% up | ||
| 17 | TG TherapeuticsTGTX · Health Care | 96.8 | PLN 39.8B | PLN 263.37 | 1.88% down | 103% up | ||
| 18 | Ligand PharmaceuticalsLGND · Health Care | 115 | PLN 23.3B | PLN 1,164.81 | 3.94% down | 44% up | ||
| 19 | Merck & CoMRK · Health Care | 134 | PLN 1.33T | PLN 539.13 | 3.61% down | 36% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0594 PLN). 25 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Bristol-Myers Squibb (12.9) have the lowest P/E ratio of the 19 pharmaceutical companies in the United States ranked here as of 20 Nov 2026, 12:18 UTC.
How many pharmaceutical companies in the United States are in this ranking?
19 are ranked by P/E ratio. 25 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 19 pharmaceutical companies in the United States ranked by P/E ratio have a combined market value of PLN 15.17T as of 20 Nov 2026, 12:18 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies in the United States by P/E ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.